ArticleInternational journal of hematology2024

Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.

Dai Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.